DeepMed Research

Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

Phase 4

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Anplag(Sarpogrelate)
Drug: Placebo

First Posted Date: 2013-06-05

Last Posted Date: 2021-04-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 151

Registration Number: NCT01869881

Locations: 🇰🇷
Korea University, Anam, Seoul, Korea, Republic of

AME Study of [14C]-YH4808 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-YH4808 200 mg

First Posted Date: 2013-04-08

Last Posted Date: 2014-07-14

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 8

Registration Number: NCT01825707

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

YH4808 Postprandial PK/PD Study in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YH4808

First Posted Date: 2013-01-04

Last Posted Date: 2014-04-15

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 21

Registration Number: NCT01761513

Locations: 🇰🇷
Yonsei University Health System(Severance Hospital), Seoul, Seodaemun-gu,Sinchon-dong, Korea, Republic of

Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)

Phase 2

Completed

Conditions: Non-erosive Reflux Disease

Interventions: Drug: YH1885L(Revaprazan)
Drug: Esomeprazole 20mg
Drug: placebo

First Posted Date: 2012-12-17

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 149

Registration Number: NCT01750437

Locations: 🇰🇷
DongA university hospital, Busan, Korea, Republic of
🇰🇷
Catholic Incheon hospital, Incheon, Korea, Republic of
🇰🇷
Kyungbook University hospital, Daegu, Korea, Republic of

and more 7 locations

Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects

Phase 1

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: YH14659
Drug: clopidogrel & aspirin

First Posted Date: 2012-08-03

Last Posted Date: 2012-08-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT01657071

Locations: 🇰🇷
Yuhan Corporation, Seoul, Korea, Republic of

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Rosuvastatin+Valsartan (Sequence 1)
Drug: Rosuvastatin+Valsartan (Sequence 2)
Drug: Rosuvastatin+Valsartan (Sequence 3)
Drug: Rosuvastatin+Valsartan (Sequence 4)
Drug: Rosuvastatin+Valsartan (Sequence 5)
Drug: Rosuvastatin+Valsartan (Sequence 6)

First Posted Date: 2012-06-01

Last Posted Date: 2012-06-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 30

Registration Number: NCT01609907

Locations: 🇰🇷
Yuhan Corporation, Seoul, Korea, Republic of

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Phase 2

Completed

Conditions: Reflux Esophagitis

Interventions: Drug: YH4808 B mg
Drug: YH4808 A mg
Drug: YH4808 C mg
Drug: Esomeprazole 40mg

First Posted Date: 2012-02-24

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 154

Registration Number: NCT01538849

Locations: 🇰🇷
Seoul ST.MARY'S HOSPITAL, Seoul, Korea, Republic of

A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR

Interventions: Drug: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)

First Posted Date: 2012-02-03

Last Posted Date: 2012-08-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 36

Registration Number: NCT01526317

Locations: 🇰🇷
Severance Hospital, Yonsei University, Seoul, Korea, Republic of

Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease

Phase 1

Completed

Conditions: Degenerative Disc Disease

Interventions: Drug: Placebo
Drug: YH14618

First Posted Date: 2012-02-03

Last Posted Date: 2015-05-29

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 48

Registration Number: NCT01526330

Locations: 🇰🇷
Kangbuk Samsung Medical Center, Seoul, Korea, Republic of

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Rheumatic Arthritis

Interventions: Biological: Placebo

First Posted Date: 2012-02-02

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 49

Registration Number: NCT01525147

Locations: 🇰🇷
Samsung Medical Center, Seoul, Irwon-dong, Gangnam-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy